Health·August 1, 2026·2 min read

Nearly 12 million cartons of Rohto eye drops recalled nationwide

FDA cites sterility concerns across multiple Cooling Eye Drops products

Logo of the U.S. Food and Drug Administration (FDA).
File photoLogo of the U.S. Food and Drug Administration (FDA).U.S. Food and Drug Administration

Nearly 12 million cartons of Rohto Cooling Eye Drops have been recalled nationwide because the manufacturer cannot assure that the products are sterile, according to a federal enforcement report. The voluntary action covers 11,960,623 cartons, containing approximately 12.5 million bottles, manufactured by Rohto-Mentholatum (Vietnam) Co., Ltd. and distributed in the United States by The Mentholatum Company of Orchard Park, New York.

The recall includes affected lots of Rohto Cooling Eye Drops All-In-One, Max Strength, Optic Glow, Digi Eye, Dry Aid, and Cool Relief, including single bottles and certain twin packs. Max Strength accounts for most of the recalled inventory, with more than 6 million single-pack cartons and nearly 500,000 twin packs included. The affected products were distributed to retailers across the United States.

The Food and Drug Administration classified the action as a Class II recall after the company initiated it on July 14, 2026. The FDA formally classified it on July 23. A Class II designation means use of the affected products could cause temporary or medically reversible health consequences, although the probability of serious harm is considered remote.

The stated reason for the recall is a lack of assurance of sterility. Eye drops must remain sterile because products applied directly to the eye bypass some of the body's natural defenses, potentially allowing microorganisms to cause irritation or infection. The recall does not mean every bottle is contaminated, but it means the manufacturer cannot guarantee that affected lots meet required sterility standards.

Consumers should stop using products whose UPC, lot number, and expiration date match the recall listings and consult the FDA enforcement report for the complete affected-lot information. Expiration dates vary by product and extend through February 2029. People who experience eye pain, redness, discharge, blurred vision, or other symptoms after using the drops should contact a healthcare professional.

Community discussion
"Do you keep eye drops at home, and will you check the lot number after hearing about this recall?"